ATE175200T1 - 3,6-disubstituierte pyridazin-derivate - Google Patents
3,6-disubstituierte pyridazin-derivateInfo
- Publication number
- ATE175200T1 ATE175200T1 AT92116413T AT92116413T ATE175200T1 AT E175200 T1 ATE175200 T1 AT E175200T1 AT 92116413 T AT92116413 T AT 92116413T AT 92116413 T AT92116413 T AT 92116413T AT E175200 T1 ATE175200 T1 AT E175200T1
- Authority
- AT
- Austria
- Prior art keywords
- disubstituted pyridazine
- pyridazine derivatives
- disorder
- disubstituted
- circulation disorder
- Prior art date
Links
- -1 3,6-DISUBSTITUTED PYRIDAZINE Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010008088 Cerebral artery embolism Diseases 0.000 abstract 1
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000004087 circulation Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000010849 intracranial embolism Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24764791 | 1991-09-26 | ||
| JP33527791 | 1991-12-18 | ||
| JP4239545A JP2730421B2 (ja) | 1991-09-26 | 1992-09-08 | ３，６−ジ置換ピリダジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE175200T1 true ATE175200T1 (de) | 1999-01-15 |
Family
ID=27332704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92116413T ATE175200T1 (de) | 1991-09-26 | 1992-09-24 | 3,6-disubstituierte pyridazin-derivate |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5324727A (de) |
| EP (1) | EP0534443B1 (de) |
| JP (1) | JP2730421B2 (de) |
| KR (1) | KR100256114B1 (de) |
| AT (1) | ATE175200T1 (de) |
| CA (1) | CA2078699A1 (de) |
| DE (1) | DE69228033T2 (de) |
| DK (1) | DK0534443T3 (de) |
| ES (1) | ES2128333T3 (de) |
| GR (1) | GR3029410T3 (de) |
| TW (1) | TW279162B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE157871T1 (de) | 1994-05-19 | 1997-09-15 | Mitsubishi Chem Corp | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind |
| CA2173493C (en) | 1994-08-09 | 2008-03-25 | Nobuhisa Watanabe | Fused pyridazine compounds |
| EP0825187A1 (de) * | 1996-08-22 | 1998-02-25 | Takeda Chemical Industries, Ltd. | Kondensierte Pyridazinylguanidine, ihre Herstellung und Verwendung |
| GB9707693D0 (en) * | 1997-04-16 | 1997-06-04 | Smithkline Beecham Plc | Novel method of treatment |
| EP1036076B1 (de) * | 1997-12-05 | 2002-09-04 | AstraZeneca UK Limited | Neuartige verbindungen |
| CN1210265C (zh) | 1998-02-19 | 2005-07-13 | 卫材株式会社 | 酞嗪衍生物和勃起障碍的治疗剂 |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
| US6689883B1 (en) | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| US7977333B2 (en) | 2000-04-20 | 2011-07-12 | Bayer Healthcare Llc | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| US6903101B1 (en) | 2000-08-10 | 2005-06-07 | Bayer Pharmaceuticals Corporation | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| US20070082910A1 (en) * | 2003-04-08 | 2007-04-12 | Mitsubishi Pharma Corporation | Specific nad(p)h oxidase inhibitor |
| WO2005080378A1 (ja) * | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| CN1984904A (zh) * | 2004-05-08 | 2007-06-20 | 神经能质公司 | 3－芳基－5,6－二取代哒嗪 |
| JP2009120486A (ja) * | 2005-12-05 | 2009-06-04 | Mitsubishi Pharma Corp | 核内オーファン受容体の新規活性化剤及びその用途 |
| KR101722289B1 (ko) | 2009-07-08 | 2017-03-31 | 데르미라 (캐나다), 인코포레이티드 | 피부과 질환 또는 증상의 치료에 유용한 ｔｏｆａ 유사체 |
| CN108137514A (zh) | 2015-07-30 | 2018-06-08 | 百时美施贵宝公司 | 芳基取代的二环杂芳基化合物 |
| EP3484878B1 (de) * | 2016-07-14 | 2020-08-19 | Bristol-Myers Squibb Company | Bicyclische heteroarylsubstituierte verbindungen |
| EP3484894B1 (de) | 2016-07-14 | 2020-08-19 | Bristol-Myers Squibb Company | Tricyclische heteroarylsubstituierte chinolin- und azachinolinverbindungen als par4-hemmer |
| CN115135315B (zh) * | 2019-12-20 | 2024-11-26 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| AU2022355409B2 (en) * | 2021-09-30 | 2025-10-16 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| EP4463454A1 (de) * | 2022-01-14 | 2024-11-20 | Jazz Pharmaceuticals Ireland Limited | Neue aminsubstituierte phthalazine und derivate als sos1-inhibitoren |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1303061A (de) * | 1969-05-03 | 1973-01-17 | ||
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPS565739B2 (de) * | 1972-10-04 | 1981-02-06 | ||
| JPS5741469B2 (de) * | 1973-12-05 | 1982-09-03 | ||
| JPS5742069B2 (de) * | 1974-01-11 | 1982-09-07 | ||
| DE2452491A1 (de) * | 1974-11-05 | 1976-05-06 | Thiemann Chem Pharm Fab | Hydrodipyrano-phthalazinverbindungen und solche verbindungen enthaltende arzneimittel |
| JPS5748972A (en) * | 1980-09-10 | 1982-03-20 | Mitsubishi Yuka Yakuhin Kk | 4-phenylphthalazine derivative |
| JPS5653659A (en) * | 1979-10-09 | 1981-05-13 | Mitsubishi Yuka Yakuhin Kk | Blood platelet coagulation suppressing agent |
| JPS5653660A (en) * | 1979-10-09 | 1981-05-13 | Mitsubishi Yuka Yakuhin Kk | 4-phenylphthalazine derivative |
| GB2063249A (en) * | 1979-10-09 | 1981-06-03 | Mitsubishi Yuka Pharma | 4-Phenylphthalazine derivatives |
| JPS57167974A (en) * | 1981-04-09 | 1982-10-16 | Mitsubishi Yuka Yakuhin Kk | Preparation of 4-phenylphthalazine derivative |
| JPS60218377A (ja) * | 1984-04-16 | 1985-11-01 | Mitsubishi Yuka Yakuhin Kk | ４−フエニルフタラジン誘導体及びそれを有効成分とする循環改善剤 |
| JPS60243074A (ja) * | 1985-04-15 | 1985-12-03 | Mitsubishi Yuka Yakuhin Kk | ４−フエニルフタラジン誘導体 |
| JPH02129181A (ja) * | 1988-11-04 | 1990-05-17 | Morishita Pharmaceut Co Ltd | １−アリール−４−（１ｈ−イミダゾール−１−イル）フタラジン誘導体 |
| JPH02129183A (ja) * | 1988-11-04 | 1990-05-17 | Morishita Pharmaceut Co Ltd | １−アニリノ−４−（１ｈ−イミダゾール−１−イル）フタラジン誘導体及びそれを有効成分とする血小板凝集抑制剤 |
| JPH02129180A (ja) * | 1988-11-04 | 1990-05-17 | Morishita Pharmaceut Co Ltd | １−（１ｈ−イミダゾール−１−イル）フタラジン誘導体 |
| JPH02129182A (ja) * | 1988-11-04 | 1990-05-17 | Morishita Pharmaceut Co Ltd | １−（１ｈ−イミダゾール−１−イル）−４−置換フェニルフタラジン誘導体及びそれらを含有する血小板凝集抑制剤 |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| JPH03106872A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―置換フェニル―４―ピリジルフタラジン誘導体 |
| JPH03106874A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | ４―ピリジル―１（２ｈ）フタラジノン |
| JPH03106873A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―ピリジルフタラジン誘導体及びそれらを含有する血小板凝集抑制剤 |
| EP0449203B1 (de) * | 1990-03-30 | 1994-12-07 | Mitsubishi Chemical Corporation | 4-Phenylphthalazin-Derivate |
-
1992
- 1992-09-02 TW TW081106956A patent/TW279162B/zh active
- 1992-09-08 JP JP4239545A patent/JP2730421B2/ja not_active Expired - Lifetime
- 1992-09-21 CA CA002078699A patent/CA2078699A1/en not_active Abandoned
- 1992-09-24 DE DE69228033T patent/DE69228033T2/de not_active Expired - Fee Related
- 1992-09-24 DK DK92116413T patent/DK0534443T3/da active
- 1992-09-24 ES ES92116413T patent/ES2128333T3/es not_active Expired - Lifetime
- 1992-09-24 EP EP92116413A patent/EP0534443B1/de not_active Expired - Lifetime
- 1992-09-24 AT AT92116413T patent/ATE175200T1/de not_active IP Right Cessation
- 1992-09-25 US US950947A patent/US5324727A/en not_active Expired - Fee Related
- 1992-09-26 KR KR1019920017593A patent/KR100256114B1/ko not_active Expired - Fee Related
-
1994
- 1994-03-21 US US08/215,426 patent/US5462941A/en not_active Expired - Fee Related
-
1999
- 1999-02-16 GR GR990400492T patent/GR3029410T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69228033T2 (de) | 1999-07-15 |
| TW279162B (de) | 1996-06-21 |
| ES2128333T3 (es) | 1999-05-16 |
| DK0534443T3 (da) | 1999-08-30 |
| JPH06135938A (ja) | 1994-05-17 |
| DE69228033D1 (de) | 1999-02-11 |
| GR3029410T3 (en) | 1999-05-28 |
| CA2078699A1 (en) | 1993-03-27 |
| EP0534443B1 (de) | 1998-12-30 |
| KR930005984A (ko) | 1993-04-20 |
| KR100256114B1 (ko) | 2000-08-01 |
| EP0534443A1 (de) | 1993-03-31 |
| JP2730421B2 (ja) | 1998-03-25 |
| US5324727A (en) | 1994-06-28 |
| US5462941A (en) | 1995-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE175200T1 (de) | 3,6-disubstituierte pyridazin-derivate | |
| EP0444196A4 (en) | Agent for treatment and prophylaxis of ischemic disease of heart or brain | |
| ES8603870A1 (es) | Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol. | |
| LTIP919A (en) | Drugs and process for preparing thereof | |
| IT8720698A0 (it) | Composizione farmaceutica adattivita' terapeutica per il trattamento della demenza senile di tipo alzheimer. | |
| HU890387D0 (en) | Process for producing amines and pharmaceutical preparations containing them | |
| IL86423A0 (en) | Pharmaceutical compositions for the treatment of alzheimer's disease | |
| NO171412C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater | |
| SE8305467L (sv) | 1,4-dihydropyridinderivat | |
| ZA887399B (en) | 4-aminopyridine derivatives | |
| NO891703D0 (no) | Farmasoeytiske sammensetninger for behandling av psoriasis. | |
| FI883961A0 (fi) | Farmaceutiskt nyttig polymorfisk modifikation av buspiron. | |
| NO172340C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktiv 1,5-dideoxy-1,5-imino-(n-omega-methyl-caproat)-l-fucitol | |
| ZA857989B (en) | 4-alkoxy-pyrido(2,3-d)pyrimidine derivatives,process for their preparation and pharmaceutical compositions containing them | |
| NO951163L (no) | Metode for antagonisering av inositol-1,4,5-trifosfat | |
| GB2204488B (en) | Pharmaceutical compositions for the treatment or prophylaxis of skin disorders | |
| PT87634A (pt) | Process for the preparation of pharmaceutical compositions containing n-imidazolyl derivatives of bicyclic compounds useful for the treatment of nephrophies | |
| FR2647785B1 (fr) | Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| DK0525252T3 (da) | Anvendelse af stafylokinase til fremstilling af en farmaceutisk sammensætning til behandling af arteriel thrombose. | |
| ZA881122B (en) | Use of n-substituted heterocyclic compounds as agents for treating coronary or cerebral disorders | |
| RU93049741A (ru) | Производные 4-гетероциклил-замещенного дигидропиридина, смесь изомеров или отдельные изомеры и их соли | |
| RU93058598A (ru) | Производные бензофурана и фармацевтическая композиция | |
| BR9714184A (pt) | Utilização de bonzoillquil-1,2,3,6-tetraidropiridinas | |
| NO170545C (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 6,21-dimethyl-19-nor-pregna-diener | |
| RU93057567A (ru) | Гетероциклические соединения, способ их получения и фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |